The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Press Releases Subscribe to our News

20. Oktober 2022

Non-Regulatory

Biosergen’s warrants of series TO2 are admitted to trading

Release
19. Oktober 2022

Non-Regulatory

Biosergen allocates shares to an underwriter in connection with the completed rights issue

Release
05. Oktober 2022

Non-Regulatory

Biosergen appoints Mangold Fondkommission to act as a liquidity provider

Release
26. September 2022

Non-Regulatory

Mangold Insight publishes interview with Biosergen’s CEO

Release
15. September 2022

Non-Regulatory

The subscription period in Biosergen’s rights issue starts today

14. September 2022

Non-Regulatory

Biosergen AB: Correction regarding ISIN code for unit rights in rights issue

Release
13. September 2022

Non-Regulatory

Biosergen AB: Biosergen publishes prospectus due to rights issue of units

Release
EU-tillväxtprospekt - Biosergen
11. Juli 2022

Non-Regulatory

3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.

Release
25. Mai 2022

Non-Regulatory

NOTICE OF ANNUAL GENERAL MEETING IN BIOSERGEN AB

Release

Non-Regulatory

KALLELSE TILL ÅRSSTÄMMA I BIOSERGEN AB

Release
02. Mai 2022

Non-Regulatory

Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus.

Release
19. April 2022

Non-Regulatory

The first subjects dosed successfully with no adverse events in the phase I trial of BSG005

Release
24. August 2021

Non-Regulatory

Biosergen’s application to start human clinical trials with BSG005 is approved

Release
19. August 2021

Non-Regulatory

Tine Kold Olesen will join Biosergen AB as Chief Operating Officer

Release
23. Juni 2021

Non-Regulatory

BIOSERGEN HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM.

Biosergen listing approval
31. Mai 2021

Non-Regulatory

The outbreak of mucormycosis (the so-called “Black Fungus”) in India is a prime example of the great need for a safer antifungal drug with true fungicidal activity

Release
19. Mai 2021

Non-Regulatory

BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM

BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)

Non-Regulatory

BIOSERGEN AVSER ATT NOTERA SINA AKTIER PÅ NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM

BIOSERGEN AVSER ATT NOTERA SINA AKTIER PÅ NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)